In prostate cancer, PTEN is frequently mutated, which leads to activation of PI3K/Akt pathway that promotes PCSC maintenance and self-renewal (Li et al., 1997; Dubrovska et al., 2009). Here, AKT1 is linked to prostate carcinoma.